Preliminary results of the Association of British Clinical Diabetologists sponsored Endobarrier in type 2 diabetes/pre-diabetes with obstructive sleep apnoea study.
Authors:
M Yadagiri, N Ashman, F Kinney, M Lang, JP Bleasdale, EN Fogden, MR Anderson, M Greenstone, C Walton, REJ Ryder
UK first NHS EndoBarrier service for advanced type 2 diabetes and obesity: one year outcomes in all patients treated.
Authors:
REJ Ryder, M Yadagiri, SP Irwin, W Burbridge, T Bashir, RA Allden, JP Bleasdale, EN Fogden, M Anderson and P Sen Gupta.
One year results of the Association of British Clinical Diabetologists (ABCD) sponsored Endobarrier in type 2 diabetes/pre-diabetes with Obstructive sleep apnoea(OSA) study
Authors:
M Yadagiri, F Kinney, J Adams, A Mohammed, JP Bleasdale, EN Fogden, MR Anderson, M Greenstone, C Walton, REJ Ryder
Improvement in renal function in chronic kidney disease in the first UK National Health Service (NHS) EndoBarrier service for uncontrolled diabesity
Authors:
REJ Ryder, P Sen Gupta, M Yadagiri, SP Irwin, W Burbridge, T Bashir, RA Allden, JP Bleasdale, EN Fogden, M Anderson and P Cockwell.
UK First NHS Endobarrier service for advanced Type 2 Diabetes and Obesity: Outcomes in all patients 6 months after device explant
Authors:
REJ Ryder, M Yadagiri, SP Irwin, W Burbridge, T Bashir, MC Wyres, ML Cull, JP Bleasdale, RA Allden, EN Fogden, M Anderson and P Sen Gupta
EndoBarrier treatment for longstanding type 2 diabetes and obesity: Outcomes one-year after EndoBarrier in 90 consecutively treated patients
Authors:
REJ Ryder, P Sen Gupta, SP Irwin, W Burbridge, T Bashir, MC Wyres, ML Cull, JP Bleasdale, RA Allden, EN Fogden, M Anderson and M Yadagiri
The National Institute for Health and Care Excellence (NICE) have called for evidence for the guideline 'Adrenal insufficiency: acute and long-term management'.
They specifically need the following information for the guideline:
The Association of British Clinical Diabetologists, the Society for Endocrinology and the Federation of the Royal Colleges of Physicians of the UK are seeking to appoint two new members of the Endocrinology and Diabetes Specialty Certificate Examinations (SCE) Standard Setting Group.
ABCD is pleased to announce the updated guidance on SGLT-2 inhibitors in type 2 diabetes. SGLT-2 inhibitors are being used increasingly not only for better diabetes control with less risk of hypoglycaemia and favourable weight loss, but also for their cardiovascular and renal benefits in people with and without diabetes. It is hoped that the updated guidance will help non-specialists to use SGLT-2 inhibitors safely and in the right patients for maximum benefit.
Two of the core objectives of the Association of British Clinical Diabetologists (ABCD) are to ensure the highest quality of care for people with diabetes and to provide a resource of information; not only for our members but also the wider multidisciplinary team and colleagues providing care for people with diabetes.
